Published in Lancet on June 02, 1973
BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg (1974) 2.14
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer (1975) 1.31
Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer (1976) 1.06
Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax (1978) 0.91
The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients. Br J Cancer (1975) 0.85
Critical analysis of treatment of stage II and stage III melanoma patients with immunotherapy. Ann Surg (1976) 0.83
Oncolytic viruses. Invest New Drugs (1999) 0.81
Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence. Br J Cancer (1978) 0.81
Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-α-induced apoptosis. Mol Cancer (2014) 0.81
New experimental and clinical data on leukaemia immunotherapy. Proc R Soc Med (1975) 0.81
Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J (1976) 0.80
Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J (1984) 0.76
Immunotherapy of guinea pigs with dermal and visceral tumor implants: comparison of living and nonliving BCG. Infect Immun (1979) 0.75
Adjuvant BCG immunotherapy for stage I and II malignant melanoma. Can Med Assoc J (1983) 0.75
Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival. Can Med Assoc J (1977) 0.75
Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J (1983) 0.75
Influence of orally administered B.C.G. on growth of transplanted rat tumours. Br J Cancer (1975) 0.75
Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75
Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol (2003) 9.10
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Macrophage-lymphocyte interaction in the antigen-induced blastogenic response of human peripheral blood leukocytes. J Immunol (1968) 4.25
The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli. J Immunol (1968) 4.24
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med (1965) 3.54
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Efficient transfer of highly resolved small DNA fragments from polyacrylamide gels to DBM paper. Gene (1980) 3.30
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol (2001) 3.02
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer (2000) 2.87
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med (1975) 2.71
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Reasons for quitting: intrinsic and extrinsic motivation for smoking cessation in a population-based sample of smokers. Addict Behav (1998) 2.10
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med (1974) 2.02
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (1990) 1.93
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
A comprehensive compilation and alignment of histones and histone genes. Nucleic Acids Res (1989) 1.91
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res (1978) 1.88
A randomized trial of self-help materials, personalized feedback, and telephone counseling with nonvolunteer smokers. J Consult Clin Psychol (1995) 1.88
Clinical trials with adriamycin. Cancer (1971) 1.86
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Spilled gallstones after laparoscopic cholecystectomy. A relevant problem? A retrospective analysis of 10,174 laparoscopic cholecystectomies. Surg Endosc (1998) 1.77
A lesson from Canada: Ontario's health insurance. N Engl J Med (1978) 1.76
Carcinoembryonic antigen: clinical correlation with chemotherapy for metastatic gastrointestinal cancer. Cancer (1974) 1.74
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Controlled multicenter trial of laparoscopic transabdominal preperitoneal hernioplasty vs Shouldice herniorrhaphy. Early results. Surg Endosc (1996) 1.71
The Polycomb-group gene, extra sex combs, encodes a nuclear member of the WD-40 repeat family. EMBO J (1995) 1.69
Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology (1991) 1.67
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Non-randomized controls in cancer clinical trials. N Engl J Med (1974) 1.67
Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis (1984) 1.67
Complications of laparoscopic cholecystectomy in Switzerland. A prospective 3-year study of 10,174 patients. Swiss Association of Laparoscopic and Thoracoscopic Surgery. Surg Endosc (1998) 1.65
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (1979) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med (1984) 1.57
Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med (1987) 1.55
Cancer immunotherapy. Can Med Assoc J (1979) 1.54
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol (1986) 1.54
Support for restrictive tobacco policies among residents of selected Minnesota communities. Am J Health Promot (1993) 1.53
A randomized trial of the impact of risk assessment and feedback on participation in mammography screening. Prev Med (1993) 1.52
HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood (1988) 1.51
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics (2001) 1.49
Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood (1990) 1.49
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Combination cancer therapy: Presidential address. Cancer Res (1972) 1.47
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Separation and collection of leukocytes. Cancer Res (1965) 1.45
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (1983) 1.45
Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res (1967) 1.44
Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv (1983) 1.43
Assessment of community-level influences on individuals' attitudes about cigarette smoking, alcohol use, and consumption of dietary fat. Am J Prev Med (1993) 1.43
Selection bias in clinical trials. J Clin Oncol (1985) 1.42
Factors related to length of complete remission in adult acute leukemia. Cancer (1980) 1.42
Angiogenesis and leukemia. Leuk Res (2001) 1.42
Immunomorphological features of prognostic significance in Dukes' Class B colorectal carcinoma. Cancer Res (1977) 1.40
The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst (1977) 1.40
Cells capable of colony formation in the peripheral blood of man. Science (1971) 1.40